

CONTENTS continued

	Page
Scientific exchange	338
Employees' health insurance program of New York State Edward D. Meacham	341
Sanitation practices and vector control at National Boy Scout Jamborees	349
WHO looks ahead. Conference report	355
Obtaining the physician's cooperation in reporting communicable disease	360
Service statistics for tuberculosis control programs	364
St. Louis encephalitis outbreak during 1956 in Grand Junction, Colo	372
Short reports and announcements:	
Improper drug source halted International mail pouch Trial of drugs for gout	288 302 315
Selwyn D. Collins, 1891–1959	324
Second National Conference on World Health	332
Results of a survey on hearing loss in children	340
Nuclear medicine	347
Publications	348
Epidemiological notes. Septicemia	354
Water pollution control. Legal note	359
Training in epidemiology	371
Signs and symptoms	376



MANAGING DIRECTOR

WILLIAM H. STEWART, M.D. Chief, Division of Public Health Methods

BOARD OF EDITORS

Edward G. McGavran, M.D., M.P.H. Chairman

FRANCIS A. ARNOLD, JR., D.D.S.
HAROLD D. CHOPE, M.D., DR.P.H.
MANDEL E. COHEN, M.D.
CARL C. DAUER, M.D.
W. PALMER DEARING, M.D.
J. STEWART HUNTER, M.A.

Charles V. Kidd, Ph.D. Alexander D. Langmuir, M.D., M.P.H.

KARL M. MASON, B.S.S.E., M.P.H. RUTH SLEEPER, R.N., M.A.

WILSON T. SOWDER, M.D., M.P.H.
MARY SWITZER

FRANKLIN H. TOP, M.D., M.P.H.

STAFF

Marcus Rosenblum Executive Editor
Winona Carson Managing Editor
Martha Seaman Asst. Managing Editor

Address correspondence to Executive Editor

Public Health Reports, published since 1878 under authority of an act of Congress of April 29 of that year, is issued monthly by the Public Health Service pursuant to the following authority of law: United States Code, title 42, sections 241, 245, 247; title 44, section 220. Use of funds for printing this publication approved by the Director of the Bureau of the Budget, August 24, 1957.

U. S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE ARTHUR S. FLEMMING, Secretary

PUBLIC HEALTH SERVICE LEROY E. BURNEY, Surgeon General

EVALUATION OF A MOUSE TEST FOR THE STANDARDIZATION OF THE IMMUNIZING POWER OF ANTI-RABIES VACCINES 1

By KARL HABEL, Assistant Surgeon, United States Public Health Service

The ideal animal test for the standardization of any vaccine should be done under conditions either similar to or at least comparable to those under which the vaccine is used clinically in human beings. The technique of performing the test should be simple and there should be no procedure in which individual differences of the technician might cause variation in results. The time required to complete a test is of practical importance since the material being tested cannot be released for clinical use until successfully meeting the requirements. Therefore the duration of the test should be sufficiently short so as not to subtract materially from the life of the vaccine.

cared for in the laboratory. The material used in testing the immulate of the description of the control of the control of the control of the control of the ideal test.

These are the requirements of the ideal test.

essi animais used should be easily available, inexpensive, and easily

Since rabies vaccine was first used it has been subjected to many types of experimental tests to determine its immunizing properties and, therefore, its efficacy in the Pasteur treatment of human beings. This subject has been reviewed recently by Webster (1), who emphasizes the general lack of positive results in the light of statistical analysis of the published protocols.

In general, the following types of tests have been used.

1. Injection of rabies virus into central nervous system (subdural, intracerebral, intraocular) followed by a course of vaccine treatment (1).— In this method results have been quite consistently negative, the same mortality usually occurring among the vaccinated and control animals. This is easily understandable, since the direct introduction

(1473)

AUGUST 16, 1940, pp. 1473-1487

Dr. Karl Habel in this classic mouse protection test establishes for an efficient rabies vaccine the minimum requirement of protection against at least 1,000 MLD (minimum lethal dose).

¹ From the Division of Biologics Control, National Institute of Health.